CN111643576A

CN111643576A - A Chinese medicinal composition for treating middle-aged and senile ophthalmic diseases, and its preparation method

Info

Publication number: CN111643576A
Application number: CN202010684184.3A
Authority: CN
Inventors: 詹容珍
Original assignee: Guangdong Zhensheng Biomedical Co ltd
Current assignee: Guangdong Zhensheng Biomedical Co ltd
Priority date: 2020-07-16
Filing date: 2020-07-16
Publication date: 2020-09-11

Abstract

The invention discloses a traditional Chinese medicine composition for treating middle-aged and elderly ophthalmic diseases and a preparation method thereof, wherein the traditional Chinese medicine composition is prepared from the following raw materials: radix rehmanniae Preparata, Cistanchis herba, flos Chrysanthemi, fructus Lycii, Corni fructus, Carthami flos, radix Morindae officinalis, flos Buddlejae and herba Erigerontis. The preparation method comprises the following steps: (1) the raw materials with the formula amount are separated from water, boiled for 2-3h by using water vapor, taken out and dried in the sun to obtain the raw material medicine; (2) crushing the raw materials except the prepared rehmannia root in the step (1) to obtain traditional Chinese medicine powder; (3) decocting radix rehmanniae Preparata in the raw materials obtained in step (1) with water for 2-3 times, filtering, mixing filtrates, adding the Chinese medicinal powder obtained in step (2), and concentrating under reduced pressure to obtain extract. The invention has simple medicinal flavor, moderate price, safety and reliability, and can effectively treat and improve diabetic retinopathy, cataract and other ophthalmic diseases.

Description

A Chinese medicinal composition for treating middle-aged and senile ophthalmic diseases, and its preparation method

Technical Field

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating middle-aged and elderly ophthalmic diseases and a preparation method thereof.

Background

With the increase of age and the aging of sense organs of the body, a plurality of diseases occur, besides common senile diseases such as hypertension, diabetes, coronary heart disease and the like, senile ophthalmic diseases such as cataract, glaucoma, diabetic retinopathy and the like are increasingly developed, and the eyesight and the life quality of the elderly are seriously affected.

CN102416106A discloses a traditional Chinese medicine for treating eye diseases of middle-aged and elderly people, which is prepared from traditional Chinese medicines such as antelope horn, puncturevine caltrop fruit, common scouring rush herb, chrysanthemum, plantain seed, selfheal, cassia seed, ginseng, dogwood, dendrobium, medlar, south dodder seed, glossy privet fruit, sea-ear shell, coptis chinensis, pipewort, akebia stem, prepared rehmannia root, yam, rhizoma alismatis, poria cocos, tree peony bark, rehmannia root, betel nut and the like, and has a remarkable curative effect on fundus hemorrhage caused by yin deficiency, liver hyperactivity and collateral channel heat injury.

CN102631557A discloses a Chinese medicinal composition for treating cataract, external oculopathy, presbyopia and myopia, which is prepared from ginseng, almond, meat 34031, cistanche, eucommia bark, achyranthes, dendrobium, wolfberry, buffalo horn, ledebouriella root, chrysanthemum, dodder seed, Chinese angelica root, prepared rhizome of rehmannia, phellodendron bark, seed of Siberian cocklebur, bitter orange, white poria, puncturevine caltrop fruit, antelope horn, cassia seed, Chinese yam, asparagus, ophiopogon root, dried rehmannia root, Ligusticum wallichii, coptis, schisandra fruit, licorice and anemarrhena rhizome.

The traditional Chinese medicine preparations for treating the ophthalmic diseases of the middle-aged and the elderly are many, but most of the traditional Chinese medicine preparations have complex compositions and high cost, and the curative effect in the practical application process is not ideal. The traditional Chinese medicine considers that the essence transformed by primordial qi of the middle-aged and the elderly is sufficient in kidney essence, the essence of the five zang-organs and the six Fu-organs can be injected to the eyes, the eyes can see the essence clearly, and the essence of the five zang-organs and the six Fu-organs can be injected to the eyes to cause the essence, and the deficiency of essence and blood can not be borne by the eyes to cause the unknown vision. Starting from the pathogenesis of the above causes, the traditional Chinese medicine composition for treating the middle-aged and old ophthalmic diseases, which has the advantages of simple medicinal flavor, safety, effectiveness and wide application range, is developed, and has important social and economic significance.

Disclosure of Invention

In order to solve the technical problems, the invention provides a traditional Chinese medicine composition for treating middle-aged and old-aged ophthalmic diseases and a preparation method thereof.

In order to achieve the purpose, the invention adopts the following technical scheme:

a traditional Chinese medicine composition for treating middle-aged and elderly ophthalmic diseases comprises the following raw materials: radix rehmanniae Preparata, Cistanchis herba, flos Chrysanthemi, fructus Lycii, Corni fructus, Carthami flos, radix Morindae officinalis, flos Buddlejae and herba Erigerontis.

Preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 0.6 to 1.5 parts of prepared rhizome of rehmannia, 0.8 to 1.2 parts of desertliving cistanche, 0.4 to 1.0 part of chrysanthemum, 0.5 to 1.2 parts of medlar, 0.1 to 0.5 part of dogwood fruit, 0.2 to 0.6 part of safflower, 0.8 to 1.5 parts of morinda officinalis, 0.1 to 0.4 part of butterflybush flower and 0.2 to 0.6 part of breviscapine.

Preferably, the mass ratio of morinda officinalis, buddleja officinalis and erigeron breviscapus is 6: 1: 2.

the invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:

(1) the raw materials with the formula amount are separated from water, boiled for 2-3h by using water vapor, taken out and dried in the sun to obtain the raw material medicine;

(2) crushing the raw materials except the prepared rehmannia root in the step (1) to obtain traditional Chinese medicine powder;

(3) decocting radix rehmanniae Preparata in the raw materials obtained in step (1) with water for 2-3 times, filtering, mixing filtrates, adding the Chinese medicinal powder obtained in step (2), and concentrating under reduced pressure to obtain extract.

Preferably, the pulverization in step (2) is to pulverize to pass through a 500-mesh sieve.

Preferably, the amount of water added in step (3) is: 5-10 times of the weight of the prepared rhizome of rehmannia. Preferably, the decocting conditions in step (3) are: decocting at 90-100 deg.C for 1-2 hr.

The invention also provides application of the traditional Chinese medicine composition in treating middle-aged and elderly ophthalmic diseases.

Preferably, the middle-aged and elderly ophthalmic diseases include cataract and diabetic retinopathy.

The invention also provides a traditional Chinese medicine preparation for treating the ophthalmic diseases of the middle-aged and the elderly.

Preferably, the traditional Chinese medicine preparation consists of the traditional Chinese medicine composition for treating the middle-aged and old-aged ophthalmic diseases and medically acceptable auxiliary materials.

Preferably, the mass percentage of the traditional Chinese medicine composition in the traditional Chinese medicine preparation is 0.1-99.9%.

Preferably, the traditional Chinese medicine preparation comprises granules, pills, capsules and tablets.

Prepared rhizome of rehmannia: is prepared from radix rehmanniae. Nature and taste: sweet and slightly wet. It enters liver and kidney meridians. The efficacy is as follows: to nourish yin, enrich blood, replenish vital essence and replenish marrow.

Cistanche deserticola: succulent stem derived from cistanche deserticola or Cistanchis herba, etc. of Orobanchaceae; nature and taste: sweet, sour, salty and warm; entering kidney and large intestine meridians; the efficacy is as follows: tonify kidney, replenish essence, moisten dryness, and smooth intestine.

Chrysanthemum: is derived from dried capitula of Chrysanthemum morifolium Ramat of Compositae. Nature and taste: sweet, bitter and slightly cold. It enters lung and liver meridians. The efficacy is as follows: dispel wind, clear heat, calm liver and improve vision.

And (4) wolfberry fruit: is prepared from dried mature fruit of Lycium barbarum L and Lycium barbarum L of Solanaceae. Nature and taste: sweet and mild; it enters liver, kidney and lung meridians. The efficacy is as follows: sweet, neutral and moist, entering liver and kidney meridians, and good at nourishing liver and kidney and improving eyesight, is a commonly used medicine for treating liver and kidney yin deficiency and hypopsia.

Cornus officinalis: dried mature pulp of Corni fructus (Cornaceae) is obtained. Nature and taste: acid and mild temperature. It enters liver and kidney meridians. The efficacy is as follows: sour, astringent and warm in nature, which mainly enters liver and kidney, and is a combination of tonifying kidney yang, tonifying kidney essence, astringing and arresting discharge.

Morinda officinalis: is derived from dried root of Morinda citrifolia. Nature and taste: sweet, pungent and slightly warm in nature; entering kidney and liver meridian; the efficacy is as follows: tonify kidney yang, strengthen tendons and bones.

Butterflybush flower: dried flower bud and inflorescence of Buddleja officinalis of Loganiaceae. Nature and taste: sweet and slightly cold; entering liver meridian; the efficacy is as follows: clear heat and purge fire, nourish liver to improve vision, remove nebula.

Erigeron breviscapus: the erigeron breviscapus contains natural chemical components with high medicinal value, such as breviscapine, and has the curative effects of resisting blood coagulation, improving microcirculation, activating blood supply of heart and brain, resisting leukoplakia canceration, reducing early renal lesion of type II diabetes, improving eyesight, etc.

The invention selects nine raw materials of prepared rhizome of rehmannia, desertliving cistanche, chrysanthemum, medlar, dogwood fruit, safflower, morinda officinalis, buddleja officinalis and erigeron breviscapus to be compounded, and can effectively treat and improve the ophthalmic diseases such as diabetic retinopathy, cataract and the like. Compared with the prior art, the invention has the advantages of simple medicine flavor, moderate price, safety and effectiveness, and is suitable for long-term administration. Meanwhile, in the experiment, when the mass ratio of the morinda officinalis, the buddleia officinalis and the erigeron breviscapus in the composition is 6: 1: 2, has better technical effects of treating and improving diabetic retinopathy and cataract.

In addition, the preparation method of the invention has the advantages of simple operation, no need of complex equipment, low cost and easy industrial production.

Detailed Description

The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.

Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.

When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The sources of the raw materials used in the present invention are not limited, and the raw materials used in the present invention are all those commonly available in the art unless otherwise specified.

A traditional Chinese medicine composition for treating middle-aged and elderly ophthalmic diseases comprises the following raw materials in parts by weight: 0.6 to 1.5 parts of prepared rhizome of rehmannia, 0.8 to 1.2 parts of desertliving cistanche, 0.4 to 1.0 part of chrysanthemum, 0.5 to 1.2 parts of medlar, 0.1 to 0.5 part of dogwood fruit, 0.2 to 0.6 part of safflower, 0.8 to 1.5 parts of morinda officinalis, 0.1 to 0.4 part of butterflybush flower and 0.2 to 0.6 part of breviscapine.

the preparation method of the traditional Chinese medicine composition comprises the following steps:

(2) crushing the raw materials except the prepared rhizome of rehmannia in the step (1) to pass through a 500-mesh sieve to obtain traditional Chinese medicine powder;

(3) decocting the raw material medicine prepared rehmannia glutinosa obtained in the step (1) with water for 2-3 times, filtering, combining the filtrates, adding the Chinese medicinal powder obtained in the step (2), and concentrating under reduced pressure to obtain an extract, namely the Chinese medicinal composition;

the adding amount of the water in the step (3) is as follows: 5-10 times of the weight of the prepared rhizome of rehmannia; the decocting conditions are as follows: decocting at 90-100 deg.C for 1-2 hr.

For further understanding of the present invention, the following detailed description will be given with reference to specific examples to explain the technical effects of the present invention.

Examples 1 to 5

The starting materials and amounts for examples 1-5 are shown in Table 1.

TABLE 1

	Example 1	Example 2	Example 3	Example 4	Example 5
						Prepared rhizome of rehmannia	0.6	1.5	0.8	1.2	1.0
Cistanche deserticola (weight portions)	0.8	1.2	0.9	1.1	1.0
						Chrysanthemum flower \ weight portion	0.4	1.0	0.7	0.8	0.6
Wolfberry fruit, part by weight	0.5	1.2	0.7	1.0	0.8
						Corni fructus, and weight part	0.1	0.5	0.3	0.4	0.2
Safflower, safflower \ weight portion	0.2	0.6	0.3	0.5	0.4
						Morinda root, radix Morindae officinalis	0.8	1.5	0.9	1.4	1.2
Buddleja officinalis \ weight part	0.1	0.4	0.15	0.3	0.2
						Erigeron breviscapus \ weight part	0.2	0.6	0.3	0.5	0.4

(1) the raw materials with the formula amount are separated from water, boiled for 3 hours by using water vapor, taken out and dried in the sun to obtain the raw material medicine;

(3) decocting the raw material medicine prepared rehmannia glutinosa prepared in the step (1) with water for 2 times, filtering, combining filtrates, adding the Chinese medicine powder obtained in the step (2), and concentrating under reduced pressure until the relative density is 1.10 at 40 ℃ to obtain an extract, namely the Chinese medicinal composition;

the adding amount of the water in the step (3) is as follows: 8 times of the weight of the prepared rhizome of rehmannia; the decocting conditions are as follows: decocting at 95 deg.C for 1.5 h.

Comparative example 1

The comparative example differs from example 5 in the absence of erigeron breviscapus.

Comparative example 2

The comparative example is different from example 5 in that morinda officinalis is 0.7 parts by weight, buddleia officinalis is 0.5 parts by weight and erigeron breviscapus is 0.7 parts by weight.

Comparative example 3

This comparative example differs from example 5 in that it does not contain safflower.

Comparative example 4

CN109528865A composition prepared in example 2.

The efficacy of the Chinese medicinal compositions prepared in examples 1 to 5 of the present invention and comparative examples 1 to 4 was evaluated.

Experimental example I Effect of xylene-induced auricle swelling in mice

120 Kunming mice with half male and female bodies and the weight of 18-22g are randomly divided into 11 groups, and 10 mice in each group are taken. Blank control group: perfusing the stomach with the same volume of normal saline; experimental groups: the traditional Chinese medicine compositions prepared in the gavage examples 1-5 and the comparative examples 1-4 respectively: the flos Carthami control group comprises flos Carthami powder (prepared by separating water from flos Carthami, steaming with water vapor for 3 hr, taking out, sun drying, pulverizing, and sieving with 500 mesh sieve), and the administration dosage is 2g/kg, and the administration is performed by intragastrically administering for 1 time every day for 7 days. 1h after the last dose, 30. mu.L of xylene was applied to both sides of the right ear of the mouse to cause inflammation. 1h after inflammation, the mice were sacrificed, and both ears were cut off along the auricle line, and left and right ear pieces were punched out with a 8mm diameter punch and weighed, respectively, to express the degree of swelling of inflammation of the ears of the mice as the difference in weight between the left and right ear pieces. The results of the experiment are shown in table 2.

TABLE 2

Note: p <0.05, P <0.01 compared to the blank control group.

As can be seen from the above table, the traditional Chinese medicine composition of the present invention can significantly reduce the swelling degree of mouse auricle caused by xylene (P <0.05), which indicates that the traditional Chinese medicine composition of the present invention has significant anti-inflammatory effect, and meanwhile, according to the group of example 3 and the group of example 5, when the mass ratio of morinda officinalis, buddleia officinalis and erigeron breviscapus in the traditional Chinese medicine composition of the present invention is 6: 1: 2, its anti-inflammatory action is preferred (P < 0.01).

Experimental example two Effect of Permeability of capillary vessels in Abdominal Cavity of mice

120 Kunming mice with half male and female bodies and the weight of 18-22g are randomly divided into 11 groups, and 10 mice in each group are taken. Blank control group: perfusing the stomach with the same volume of normal saline; experimental groups: the traditional Chinese medicine compositions prepared in the gavage examples 1-5 and the comparative examples 1-4 respectively: the flos Carthami control group comprises flos Carthami powder (prepared by separating water from flos Carthami, steaming with water vapor for 3 hr, taking out, sun drying, pulverizing, and sieving with 500 mesh sieve), and the administration dosage is 2g/kg, and the administration is performed by intragastrically administering for 1 time every day for 7 days. 1h after the last administration, the mice were injected with 0.5% Evans blue and 0.1mL/10g intravenously at the tail, immediately injected with 0.6% acetic acid intraperitoneally, sacrificed after 20min, and then the mice were sacrificed by injecting 6mL distilled water into the abdominal cavity, gently massaging the abdomen, sucking out the washing solution with a syringe, diluting to 10mL, centrifuging, taking the supernatant, performing color comparison at 590nm with an ultraviolet spectrophotometer, and measuring the absorbance value (OD). The results are shown in Table 3.

TABLE 3

Note: p <0.05, P <0.01 compared to the blank control group.

As can be seen from the above table, the traditional Chinese medicine composition of the present invention can significantly inhibit the permeability of the mouse peritoneal capillary (P <0.05), and meanwhile, according to the group of example 3 and the group of example 5, when the mass ratio of morinda officinalis, buddleja officinalis and erigeron breviscapus in the composition is 6: 1: 2, the effect of inhibiting the permeability of the capillary vessels in the abdominal cavity of the mouse is better (P < 0.01).

Experimental example Effect of Tritriose uropathy rat retina VEGF and PEDF

Taking SD rats, randomly dividing the SD rats into a blank control group and a diabetes mellitus building group, and after all the rats are fasted for 16 hours, injecting 55mg/kg of 0.01mol/L, pH citric acid buffer solution of 4.4 into the abdominal cavity of the rats in the blank control group; diabetes model rats were injected intraperitoneally with 1% Streptozotocin (STZ)55mg/kg (STZ dissolved in 0.01mol/L, pH in 4.4 citric acid buffer). After one week of molding, blood is taken from tail vein to measure fasting blood glucose value, and the blood glucose is more than or equal to 16.7mmol/L as the successful standard of molding.

The diabetic rats successfully modeled were randomly divided into 12 groups of 10 rats each according to blood sugar and body weight. Model control and blank control: perfusing the stomach with the same volume of normal saline; experimental groups: the traditional Chinese medicine compositions prepared in the gavage examples 1-5 and the comparative examples 1-4 respectively: the flos Carthami control group comprises flos Carthami powder (prepared by separating flos Carthami with water, steaming with water vapor for 3 hr, taking out, sun drying, pulverizing, and sieving with 500 mesh sieve), and the administration dosage is 2g/kg, and the administration is performed by intragastrically administering for 1 time every day for 6 months. After the administration, rats were anesthetized, bilateral eyeballs were removed, fixed with paraformaldehyde solution for one day, the cornea was punctured, fixed again, paraffin-embedded, sectioned, immunohistochemically, and then the integrated optical density and area of VEGF and PEDF positive reactions were measured, and the average optical density value (x ± s) was calculated. The results of the experiment are shown in table 4.

TABLE 4

Note: # P <0.01 compared to placebo; p <0.05, P <0.01 compared to model control.

As can be seen from the above table, the expression of VEGF was significantly increased in rat retina of the model control group (P <0.01) and the expression of PEDF was significantly decreased (P <0.01) compared to the blank control group. Compared with the model control group, the traditional Chinese medicine composition of the groups 1 to 5 of the invention can obviously reduce the expression of VEGF (P <0.05) in rat retina and increase the expression of PEDF (P <0.05), and meanwhile, according to the groups 3 and 5 of the embodiment, when the mass ratio of the morinda officinalis, the buddleia officinalis and the erigeron breviscapus in the composition is 6: 1: at 2, there was a very significant decrease in rat retinal VEGF expression (P < 0.01).

Experimental example Effect of MDA content and antioxidase Activity in lens of four D-galactose cataract model rat

Wistar rats were taken and randomly divided into 12 groups of 10 rats each. Blank control group: injecting 20mL/kg of normal saline into the abdominal cavity every day for 14 continuous days, and performing intragastric administration of normal saline with the same volume as the administration amount once a day; model control group: injecting 20mL/kg of 80% D-galactose solution into the abdominal cavity continuously for 14 days, and performing intragastric administration and administration with the same volume of normal saline once a day; experimental and safflower control groups: injecting 80% D-galactose solution 20mL/kg into abdominal cavity every day for 14 days continuously, and respectively gavage the Chinese medicinal composition of examples 1-5, the Chinese medicinal composition of comparative examples 1-4, and Carthami flos Chinese medicinal powder (the preparation method of Carthami flos Chinese medicinal powder comprises separating Carthami flos with water, steaming with water vapor for 3 hr, taking out, sun drying, pulverizing, and sieving with 500 mesh sieve), wherein the administration amount is 2g/kg once a day. After 12h of last gavage administration, each group of rats was sacrificed, both eyes were removed, crystalline lenses were separated, washed with 4 ℃ distilled water, and then water was sucked off with filter paper, weighed, and then physiological saline was added at a W/V of 1:9, ground in an ice bath, frozen and centrifuged, and the supernatant was taken out to prepare 10% crystalline lens homogenate, and MDA content, SOD activity and GSH-Px activity in the crystalline lenses were measured. The results are shown in Table 5.

TABLE 5

Note: # P <0.05 compared to blank control; p <0.05 compared to model control.

As can be seen from the above table, compared with the blank control group, the MDA content of the model control group is significantly increased, and the activities of SOD and GSH-Px are significantly reduced (P < 0.05); compared with the model control group, the rats using the traditional Chinese medicine composition of the invention in the examples 1-5 have significantly reduced MDA content (P <0.05), significantly increased SOD and GSH-Px activities (P <0.05), and meanwhile, according to the examples 3 and 5, when the mass ratio of the morinda officinalis, the buddleia officinalis and the erigeron breviscapus in the traditional Chinese medicine composition of the invention is 6: 1: 2, the effect is better.

In conclusion, nine raw materials of prepared rehmannia root, desertliving cistanche, chrysanthemum, medlar, dogwood fruit, safflower, morinda officinalis, buddleja officinalis and erigeron breviscapus are selected and compounded, so that the ophthalmic diseases such as diabetic retinopathy, cataract and the like can be effectively treated and improved.

Compared with the prior art, the invention has the advantages of simple medicine flavor, moderate price, safety and effectiveness, and is suitable for long-term administration. Meanwhile, in the experiment, when the mass ratio of the morinda officinalis, the buddleia officinalis and the erigeron breviscapus in the composition is 6: 1: 2, has better technical effects of treating and improving diabetic retinopathy and cataract.

Meanwhile, the preparation method disclosed by the invention is simple to operate, free of complex equipment, low in cost and easy for industrial production.

The present invention has been further described with reference to specific embodiments, which are only exemplary and do not limit the scope of the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.

Claims

1. A traditional Chinese medicine composition for treating middle-aged and elderly ophthalmic diseases is characterized by comprising the following raw materials: radix rehmanniae Preparata, Cistanchis herba, flos Chrysanthemi, fructus Lycii, Corni fructus, Carthami flos, radix Morindae officinalis, flos Buddlejae and herba Erigerontis.

2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 0.6 to 1.5 parts of prepared rhizome of rehmannia, 0.8 to 1.2 parts of desertliving cistanche, 0.4 to 1.0 part of chrysanthemum, 0.5 to 1.2 parts of medlar, 0.1 to 0.5 part of dogwood fruit, 0.2 to 0.6 part of safflower, 0.8 to 1.5 parts of morinda officinalis, 0.1 to 0.4 part of butterflybush flower and 0.2 to 0.6 part of breviscapine.

3. The traditional Chinese medicine composition of claim 1, wherein the mass ratio of morinda officinalis, buddleia officinalis and erigeron breviscapus is 6: 1: 2.

4. a method for preparing a Chinese medicinal composition according to any one of claims 1 to 3, comprising the steps of:

5. The method according to claim 4, wherein the conditions for the decoction in the step (3) are: decocting at 85-95 deg.C for 1-2 hr.

6. Use of a Chinese medicinal composition according to any one of claims 1 to 3 for the treatment of ophthalmic disorders in the middle and old aged.

7. The use according to claim 7, wherein the ophthalmic diseases of the middle and old aged include cataract and diabetic retinopathy.

8. A Chinese medicinal preparation for treating middle-aged and elderly ophthalmic diseases, which comprises the Chinese medicinal composition of any one of claims 1-4 and medically acceptable adjuvants.

9. The traditional Chinese medicine preparation of claim 8, wherein the traditional Chinese medicine composition is 0.1-99.9% by mass of the traditional Chinese medicine preparation.

10. The traditional Chinese medicine preparation of claim 8, wherein the traditional Chinese medicine preparation comprises granules, pills, capsules and tablets.